CD38-NAMPT-p21 signaling promotes stress adaptation in CLL

Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the United States, accounting for ~30% of new diagnoses and ~4,000 deaths annually. High CD38 expression is a well-established marker of poor prognosis, yet the mechanistic basis of CD38-mediated treatment failure has remained incompletely understood. Here, we demonstrate that CD38 functions not merely as a prognostic biomarker but as a metabolic and signaling regulator that equips CLL cells to withstand cytotoxic and hypoxic stress. Using MEC-1 cells engineered to express CD38, we identified a CD38-NAMPT-p21 survival axis that confers resistance to fludarabine and hypoxia. CD38 NADase activity promoted NAMPT upregulation and AKT activation and was associated with accumulation of cytoplasmic p21. This CD38-dependent phenotype was lost in cells expressing a catalytically inactive CD38 mutant and was also reversed by pharmacologic inhibition of NAMPT (FK866) or suppression of p21 (UC2288). Analysis of three independent single-cell RNA-sequencing datasets of primary CLL further showed that naturally occurring CD38-positive CLL cells exhibit increased NAMPT expression and related stress-response signaling. Analysis of larger primary CLL cohorts further linked NAMPT expression to AKT and hypoxia signatures, providing additional support for the relevance of this pathway in patient-derived CLL. Together, these findings identify CD38-NAMPT-p21 signaling as an important mechanism of stress adaptation in CLL and suggest that targeting NAD⁺ metabolism and p21-mediated survival pathways may represent a potential strategy for CD38-high disease.

Authors

Institutions

Publication Details

Journal
bioRxiv (Cold Spring Harbor Laboratory)
Published
2026-11-18
DOI
https://doi.org/10.64898/2026.11.16.766865
Primary Topic
Chronic Lymphocytic Leukemia Research
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

CD38-NAMPT-p21 signaling promotes stress adaptation in CLL

Aneel Paulus, Eduardo N. Chini, Claudia C.S. Chini, Yuki Hamada et al.
bioRxiv (Cold Spring Harbor Laboratory)
Chronic Lymphocytic Leukemia Research
preprint

CD38-NAMPT-p21 signaling promotes stress adaptation in CLL

Aneel Paulus, Eduardo N. Chini, Claudia C.S. Chini, Yuki Hamada, Bing Han, Anders Berglund, Esteban Braggio, GINA CICCIO LOPEZ, ASHER CHANAN-KHAN
preprint en

Abstract

Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the United States, accounting for ~30% of new diagnoses and ~4,000 deaths annually. High CD38 expression is a well-established marker of poor prognosis, yet the mechanistic basis of CD38-mediated treatment failure has remained incompletely understood. Here, we demonstrate that CD38 functions not merely as a prognostic biomarker but as a metabolic and signaling regulator that equips CLL cells to withstand cytotoxic and hypoxic stress. Using MEC-1 cells engineered to express CD38, we identified a CD38-NAMPT-p21 survival axis that confers resistance to fludarabine and hypoxia. CD38 NADase activity promoted NAMPT upregulation and AKT activation and was associated with accumulation of cytoplasmic p21. This CD38-dependent phenotype was lost in cells expressing a catalytically inactive CD38 mutant and was also reversed by pharmacologic inhibition of NAMPT (FK866) or suppression of p21 (UC2288). Analysis of three independent single-cell RNA-sequencing datasets of primary CLL further showed that naturally occurring CD38-positive CLL cells exhibit increased NAMPT expression and related stress-response signaling. Analysis of larger primary CLL cohorts further linked NAMPT expression to AKT and hypoxia signatures, providing additional support for the relevance of this pathway in patient-derived CLL. Together, these findings identify CD38-NAMPT-p21 signaling as an important mechanism of stress adaptation in CLL and suggest that targeting NAD⁺ metabolism and p21-mediated survival pathways may represent a potential strategy for CD38-high disease.

bioRxiv (Cold Spring Harbor Laboratory)
Mayo Clinic (US)
National Institutes of Health
Good health and well-being
Chronic Lymphocytic Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon